Metrics as of 10/17/2026, 08:40 AM (Berlin time), refresh in progress.
ImmuPharma Stock
ImmuPharma PLC
Company data
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United Kingdom
- CEO
- Timothy Paul McCarthy
- Employees
- 7
- Market cap
- £24 M
- IPO
- 28/10/2003
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics in the United Kingdom. Its peptide-based therapeutics focuses on autoimmunity and inflammation, and anti-infectives therapeutic areas. The company’s lead product candidate includes P140, a peptide technology platform, which…
ImmuPharma stock: price history
1D
+4.1%
1W
-3.8%
1M
+10.0%
6M
-19.8%
YTD
-37.9%
1Y
-61.1%
2Y
+96.4%
5Y
-47.3%
10Y
-89.8%
Next earnings date
Next earnings date
25/05/2027 (in 220 days)
Volatility around earnings
~7% stronger price swings than usual
Ask the agents about ImmuPharma
ImmuPharma stock metrics
P/E
-3.08
P/B
11.82
EV/EBITDA
-6.57
RETURN ON EQUITY
-258.1%
NET MARGIN
0.0%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
82.1%
FLOAT SHARES
512,207,846
AVG. DAILY VOLUME (30D)
2,333,775
Dividends
Comparable stocks
Frequently asked questions about ImmuPharma stock
What does ImmuPharma do?
ImmuPharma PLC is a company in the Healthcare sector, Biotechnology industry, headquartered in United Kingdom.
The CEO is Timothy Paul McCarthy, the company employs around 7 people.
The IPO was on 28/10/2003; the stock trades on LSE under the ticker IMM.L.
When does ImmuPharma report next?
The next earnings date is 25/05/2027.
Around past earnings, price swings were roughly 7% stronger than usual.
Does ImmuPharma pay a dividend?
Yes. The last dividend was £1.00 per share.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to ImmuPharma?
Comparable stocks include Vertex Pharmaceuticals, Moderna, Regeneron Pharmaceuticals, argenx, Revolution Medicines, BeOne Medicines, Incyte and Genmab A/S.
How can I get ImmuPharma stock analyzed?
Clicking "Analyze stock" lets five strategies assess ImmuPharma against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.